| Literature DB >> 33576579 |
Maria Pulkkinen1,2, Irma Jousela1,3, Harri Sintonen4, Janne Engblom5,6, Sanna Salanterä2,7, Kristiina Junttila1,2,8.
Abstract
AIMS: To explore the effectiveness of a new perioperative practice model on anxiety and health-related quality of life in patients undergoing total hip arthroplasty and total knee arthroplasty under spinal anaesthesia.Entities:
Keywords: anxiety; continuity; health-related quality of life; nursing; perioperative practice model; randomized clinical trial
Mesh:
Year: 2021 PMID: 33576579 PMCID: PMC8186686 DOI: 10.1002/nop2.776
Source DB: PubMed Journal: Nurs Open ISSN: 2054-1058
Characteristics of the study participants (total n = 453)
| Intervention group |
Age (mean, 67 ( |
ASA 1
|
ASA 2
|
ASA3
|
ASA 4
|
Total
|
|---|---|---|---|---|---|---|
| Female THA | 67.2 (8.79) | 12 | 44 | 32 | 1 | 89 (38.5%) |
| Male THA | 62.9 (11.52) | 9 | 23 | 22 | 1 | 55 (23.8%) |
| Female TKA | 71.4 (10.99) | 6 | 23 | 28 | 0 | 57 (24.7%) |
| Male TKA | 66.1 (8.53) | 3 | 12 | 15 | 0 | 30 (13.0%) |
ASA 1: A normal healthy individual. Fit, non‐obese (BMI under 30), nonsmoker with good exercise tolerance.
ASA 2: A patient with mild systematic disease. Individual with no functional limitations and well‐controlled disease (e.g. treated hypertension, obesity with BMI under 35, frequent social drinker or is a cigarette smoker).
ASA 3: A patient with severe systematic disease that is not life‐threatening. A patient with some functional limitations as result of disease (e.g. poorly treated hypertension or diabetes, morbid obesity, chronic renal failure a bronchospastic disease with intermittent exacerbation, stable angina, implanted pacemaker).
ASA 4: A patient with a severe systematic disease that is a constant threat to life. A patient with functional limitation from severe, life‐threatening disease (e.g. unsuitable angina, poorly controlled COPD, symptomatic CHF, recent (less than three months ago) myocardial infarction or stroke (Doyle & Garmon, 2018)).
Figure 1Flow chart of the study participants and reasons for exclusion and dropout
HRQoL total index scores of 15D at baseline and follow‐up
| HRQoL mean, ( | HRQoL mean, ( | Difference of means | 95% CI |
| |
|---|---|---|---|---|---|
| Intervention group all | 0.827 (0.08) | 0.886 (0.08) | 0.059 | [0.036, 0.081] | <0.001 |
| THA all (female + male) | 0.826 (0.09) | 0.894 (0.08) | 0.068 | [0.048, 0.087] | <0.001 |
| THA female | 0.814 (0.08) | 0.886 (0.08) | 0.072 | [0.032, 0.111] | <0.001 |
| THA male | 0.844 (0.09) | 0.898 (0.08) | 0.054 | [0.003, 0.105] | 0.026 |
| TKA all female + male) | 0.830 (0.08) | 0.876 (0.08) | 0.046 | [0.018, 0.074] | <0.001 |
| TKA female | 0.826 (0.08) | 0.873 (0.07) | 0.047 | [0.014, 0.108] | 0.271 |
| TKA male | 0.837 (0.08) | 0.883 (0.09) | 0.045 | [−0.031, 0.123] | 0.615 |
| Control group all | 0.847 (0.07) | 0.902 (0.08) | 0.055 | [0.031, 0.078] | <0.001 |
| THA all (female + male) | 0.849 (0.07) | 0.920 (0.06) | 0.071 | [0.049, 0.092] | <0.001 |
| THA female | 0.835 (0.07) | 0.922 (0.06) | 0.086 | [0.041, 0.132] | <0.001 |
| THA male | 0.863 (0.07) | 0.917 (0.07) | 0.053 | [0.004, 0.102] | 0.021 |
| TKA (female + male) | 0.842 (0.07) | 0.872 (0.10) | 0.029 | [0.000, 0.058] | 0.046 |
| TKA female | 0.840 (0.07) | 0.882 (0.10) | 0.041 | [−0.021, 0.104] | 0.465 |
| TKA male | 0.857 (0.06) | 0.847 (0.10) | −0.010 | [−0.097, 0.076] | 1.000 |
| HRQoL total index scores of 15D baseline between intervention group and control group | |||||
| Intervention group | 0.827 (0.08) | −0.019 | [−0.040, 0.001] | 0.075 | |
| Control group | 0.847 (0.07) | ||||
| HRQoL total index scores of 15D follow‐up between intervention group and control group | |||||
| Intervention group | 0.886 (0.08) | −0.016 | [−0.041, 0.008] | 0.343 | |
| Control group | 0.902 (0.08) | ||||
t‐test of a multivariate model with Tukey–Kramer adjustments.
Classification of the changes in the 15D scores from baseline to follow‐up into global assessment scale categories and the distribution of patients into these categories
| Global assessment category | Limits for change in the 15D score (Alanne et al. | Distribution of patients (%) | |
|---|---|---|---|
| Intervention group | Control group | ||
| Much better | >0.035 | 60.3 | 62.6 |
| Slightly better | 0.15–0.035 | 14.4 | 11.4 |
| Much the same (no change) | >−0.015 and < 0.015 | 13.0 | 13.0 |
| Slightly worse | −0.015 to −0.035 | 7.5 | 7.3 |
| Much worse | <−0.035 | 4.8 | 5.7 |
Figure 2The mean 15D profiles of both groups at baseline and at follow‐up. The dimensions with a statistically significant improvement (p <.05) are marked with an asterisk*
The mean state anxiety (STAI‐S) and trait anxiety (STAI‐T) scores at baseline and follow‐up
| STAI‐S Baseline mean ( | STAI‐S Follow‐up mean and ( | Difference of means | 95% CI |
| |
|---|---|---|---|---|---|
| Intervention group all | 38.06 (11.40) | 33.14 (10.63) | −4.91 | [−8.02, −1.79] | <0.001 |
| Female THA | 41.12 (12.07) | 33.03 (10.10) | −8.09 | [−13.92, −2.27] | <0.001 |
| Male THA | 36.39 (9.14) | 33.17 (11.88) | −3.22 | [−10.55, 4.11] | 0.884 |
| Female TKA | 36.11 (12.02) | 32.27 (10.83) | −3.85 | [−11.53, 3.82] | 0.787 |
| Male TKA | 35.51 (10.64) | 35.33 (9.55) | −0.16 | [−10.53, 10.21] | 0.000 |
| Control group all | 36.98 (11.80) | 31.77 (11.37) | −5.21 | [−8.47, −1.95] | <0.001 |
| Female THA | 39.28 (12.85) | 31.46 (11.41) | −7.82 | [−14.21, −1.44] | <0.05 |
| Male THA | 33.51 (11.60) | 29.00 (10.25) | −4.51 | [−11.71, 2.67] | 0.543 |
| Female TKA | 36.80 (10.71) | 34.67 (13.07) | −2.12 | [−9.86, 5.61] | 0.991 |
| Male TKA | 38.72 (9.10) | 34.20 (9.25) | −4.52 | [−16.37, 7.33] | 0.940 |
| STAI‐S Baseline scores between the intervention group all and control group all | |||||
| Intervention group | 38.06 (11.40) | 1.07 | [−1.95, 4.10] | 0.799 | |
| Control group | 36.98 (11.80) | ||||
| STAI‐S Follow‐up scores between the intervention group all and control group all | |||||
| Intervention group | 33.14 (10.63) | 1.37 | [−1.96, 4.70] | 0.714 | |
| Control group | 31.77 (11.37) | ||||
t‐test of multivariate model with Tukey–Kramer adjustments.